Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1997-01-13
1999-11-02
Hutzell, Paula K.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 691, 4353201, 435325, 4352523, 4351723, 530350, 530300, G01N 3353, C07H 2104, C12N 1512, C12N 1563
Patent
active
059768142
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
Throughout this application, various publications are referenced in parenthesis by Author and year. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the art to which this invention pertains.
Neuropeptides are small peptides originating from large precursor proteins synthesized by peptidergic neurons and endocrine/paracrine cells. They hold promise for treatment of neurological, psychiatric, and endocrine disorders (De Wied, 1990). Often the precursors contain multiple biologically active peptides. There is great diversity of neuropeptides in the brain caused by alternative splicing of primary gene transcripts and differential precursor processing. The neuropeptide receptors serve to discriminate between ligands and to activate the appropriate signals. Thus, it is expected that the receptors for neuropeptides consist of a large number of members.
Neuropeptide Y (NPY), a 36-amino acid peptide, is the most abundant neuropeptide to be identified in mammalian brain. NPY is an important regulator in both the central and peripheral nervous systems (Heilig et al., 1990) and influences a diverse range of physiological parameters, including effects on psychomotor activity, food intake, central endocrine secretion, and vasoactivity in the cardiovascular system. High concentrations of NPY are found in the sympathetic nerves supplying the coronary, cerebral, and renal vasculature and has contributed to vasoconstriction. NPY binding sites have been identified in a variety of tissues, including spleen (Lundberg et al., 1988), intestinal membranes, brain (Hinson et al., 1988), aortic smooth muscle (Mihara et al., 1989), kidney, testis, and placenta (Dumont et al., 1992). In addition, binding sites have been reported in a number of rat and human cell lines (eg. Y1 in SK-N-MC, MC-IXC, CHP-212, and PC12 cells; Y2 in SK-N-Be(2), CHP-234, and SMS-MSN)(Aakerlund et al., 1990; Grundemar et al., 1993).
NPY forms a family (called the pancreatic polypeptide family) together with pancreatic polypeptide (PP) and peptide YY (PYY) which all consist of 36 amino acids and have a common tertiary structure, the so-called PP-fold (Glover et al., 1985). Specific features of this family include a polyproline helix in residues 1 through 8, a .beta.-turn in residues 9 through 14, an .alpha.-helix in residues 15 through 30, an outward-projecting C-terminus in residues 30 through 36, and a carboxy terminal amide which appears to be critical for biological activity (Schwartz et al., 1990). The C-terminal amidated residue of these peptides is essential for biological activity (Wahlestedt et al., 1986). Studies with peptide fragments of NPY have indicated that multiple NPY receptor subtypes exist (Wahlestedt et al., 1986). Three major NPY receptor subtypes (Y1, Y2 and Y3) have been defined by pharmacological criteria, with a fourth "atypical" Y1 receptor that has been proposed to regulate feeding behavior. The only NPY receptor which has been cloned to date is the Y1 receptor gene, from mouse (Eva et al., 1992), rat (Eva et al., 1990), and human (Larhammar et al., 1992). One of the key pharmacological features which distinguish Y1 and Y2 is the fact that the Y1 receptor (and not the Y2 receptor) responds to an analog of NPY modified at residues 31 and 34 ([Leu31,Pro34]NPY), whereas the Y2 receptor (and not the Y1 receptor) has high affinity for the NPY peptide carboxyl-terminal fragment NPY-(13-36)(Wahlstedt et al., 1986; Fuhlendorff et al., 1990).
Receptor genes for the other two structurally related peptides, peptide YY (PYY) and pancreatic polypeptide (PP), also have not been cloned. Peptide YY occurs mainly in endocrine cells in the lower gastrointestinal tract (Bottcher et al., 1984). Receptors for PYY were first described in the rat small intestine (Laburthe et al., 1986). This receptor has been defined as PYY-preferring because it di
REFERENCES:
patent: 4839343 (1989-06-01), Waeber et al.
patent: 5026685 (1991-06-01), Boublik et al.
patent: 5053337 (1991-10-01), Weinshank et al.
patent: 5328899 (1994-07-01), Boublik et al.
patent: 5506258 (1996-04-01), Christophe et al.
patent: 5571695 (1996-11-01), Selbie et al.
patent: 5602024 (1997-02-01), Gerald et al.
Herzog, et al. "Cloned Human Neuropeptide Y Receptor Couples to Two Different Second Messenger Systems" PNAS (1992) 89(13): 5794-5798.
Larhammar, et al., "Cloning and Functional Expression of a Human Neuropeptide Y/Peptide YY Receptor of the Y1 Type" The Journal of Biological Chemistry (1992) 267(16): 10935-10938.
Lundberg, et al., "Comparative Immunohistochemical and Biochemical Analysis of Pancreatic Polypeptide-Like Peptides with Special Reference to Presence of Neuropeptide Y in Central and Peripherial Neurons" The Journal of Neuroscience (1984) 4(9): 2376-2386.
Wahlestedt, C., et al., "Identification of Cultured Cells Selectively Expressing Y1-, Y2-, or Y3-Type Receptors for Neuropeptide Y/Peptide YY" Life Sciences (1991) 50: P17-PL12.
Wahlestedt, C., et al., "Neuropeptide Y Receptor Subtypes, Y1and Y2" Annals of the New York Academy of Sciences (1990) 611: 7-26; and Whitcomb, D.C., et al., "Characterization of Saturable Binding Sites For Circulating Pancreatic Polypeptide In Rat Brain" Am. J. Physiol. (1990) 259: G687-G691.
Deferens Eur. J. Pharm. (1990) 186: 105-114.
Kotz, C.M., et al., "The Effect of Norbinaltorphimine, .beta. -Funaltrexzmine and Naltrindole on NPY-Induced Feeding" Brain Research (1993) 631; 325-328.
Krause, J., et al., "Neuropeptide Y1 Subtype Pharmacology of a Recombinantly Expressed Neuropeptide Receptor" Mol. Pharm. (1992) 41: 817-821.
Leibo S.F., et al., "Blockade of Natural and Neuropeptide Y-Induced Carbohydrate Feeding By a Receptor Antagonist PYX -2" NeuroReport (1992) 3(11): 1023-1026.
Patents Abstracts of Japan (1992) 16(265): Abstract No. C-0951, corresponding to Japanese Patent Application No. 4 063 594, published Feb. 28, 1992.
Schwartz, T.W., et al., "Receptors of Phaechromocytoma Cells For Two Members of the PP-Fold Family-NPY and PP" FEBS Letters (1987) 225(1):209-214.
Vander, A.J., et al., Human Physiology, McGraw-Hill Publishing Co., (1990) pp. 207-210.
Wahlestedt, C., et al., "Neuropeptide Y-Related Peptides and Their Receptors-Are the Receptors Potential Therapeutic Drug Targets?" Annu. Rev. Pharmacol. Toxicol. (1993) 32: 309-352; and.
Weinberg, D.H., et al., "Cloning and Expression of a Novel Neuropeptide Y Receptor" J. Biol. Chem. (1996) 271(28): 16435-16438.
Bard, J.A., et al., "Cloning and Functional Expression of a Human Y4 Subtype Receptor For Pancreatic Polypeptide, Neuropeptide Y, and Peptide YY" J. Biol. Chem. (1995) 270(45): 26762-26765.
Doughty, M.B., et al., "Benextramine-Neuropeptide Y Receptor Interactions : Contribution of the Benzylic Moieties to [.sup.3 H] Neuropeptide Y Displacement Activity" J. Med. Chem. (1993) 36(2): 272-279.
Gehlert, D.R., "Subtypes of Receptors for Neuropeptide Y: Implications for the Targeting of Therapeutics" Life Science (1994) 55(8): 551-562.
George, S.T., et al., "High-Efficiency Expression of Mammalian .beta. -Adrenergic Receptor in Baculovirus-Infected Insect Cells" Biochemical and Biophysical Research Communications (1989) 163(3): 1265-1269.
Gerald, C., et al., "A Receptor Subtype Involved in Neuropeptide-Y-Induced Food Intake" Nature (1996) 382: 168-171.
Gilbert, W., et al., "Characterization of Specific Pancreatic Polypeptide Receptors on Basolateral Membranes of the Canine Small Intestine" PNAS (1988) 85: 4745-4749.
Goadsby, P.J., and Edvinsson, L., "Examination of the Involvement of Neuropeptide Y (NPY) in Cerebral Autoregulation Using the Novel NPY Antagonist PP56" Neuropeptides (1993) 24(1): 27-33.
Hu, Y., et al., "Identification of a Novel Hypothalamic Neuropeptide Y Receptor Associated With Feeding Behavior" Journal of Biological Chemistry (1996) 271(42): 26315-26319.
Jorgensen, I. Ch., et al., Structure-Function Studies on Neuropept
Bard Jonathan A.
Branchek Theresa
Walker Mary W.
Weinshank Richard L.
Basi Nirmal S.
Hutzell Paula K.
Synaptic Pharmaceutical Corporation
White John P.
LandOfFree
DNA encoding a human neuropeptide Y/peptide YY/pancreatic polype does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA encoding a human neuropeptide Y/peptide YY/pancreatic polype, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA encoding a human neuropeptide Y/peptide YY/pancreatic polype will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2133330